MA
IMDX

MUFG Americas’s Insight Molecular Diagnostics IMDX Stock Holding History

MUFG Americas’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-19
Closed -$2K – 1205
2017
Q2 		$2K Hold
19
– – ﹤0.01% 1066
2017
Q1 		$2K Hold
19
– – ﹤0.01% 1060
2016
Q4 		$3K Buy
+19
New +$2.09K ﹤0.01% 980

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FM
Family Management New York $834M AUM 20.83% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

MUFG Americas's IMDX Position: Q3 2017 in Review

MUFG Americas sold out of Insight Molecular Diagnostics (IMDX) in Q3 2017, closing a stake of 19 shares — an estimated $2K sold.

MUFG Americas first reported a position in IMDX in Q4 2016 and held it in 3 quarters. The position peaked at $3K in Q4 2016. 37 funds tracked by Wall St. Rank hold IMDX as of Q3 2017.

  • MUFG Americas reported no remaining Insight Molecular Diagnostics position as of Q3 2017 after selling out during the quarter.
  • MUFG Americas sold 19 Insight Molecular Diagnostics shares in Q3 2017, an estimated $2K.
  • MUFG Americas first reported a position in Insight Molecular Diagnostics in Q4 2016 and held it in 3 quarters.
  • MUFG Americas's Insight Molecular Diagnostics position peaked at $3K in Q4 2016.
  • 37 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2017.

Based on MUFG Americas's 13F filing for Q3 2017, filed 13 Nov 2017.